Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory

M. Cella1*, D. Stahl2, S. Morris3, R. S. E. Keefe4, M. D. Bell5 and T. Wykes1

1 Department of Psychology, King’s College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK
2 Department of Biostatistics, King’s College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK
3 Division of Adult Translational Research, National Institute of Mental Health, North Bethesda, MD, USA
4 Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
5 Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA

Background. Recent theories suggest that poor working memory (WM) may be the cognitive underpinning of negative symptoms in people with schizophrenia. In this study, we first explore the effect of cognitive remediation (CR) on two clusters of negative symptoms (i.e. expressive and social amotivation), and then assess the relevance of WM gains as a possible mediator of symptom improvement.

Method. Data were accessed for 309 people with schizophrenia from the NIMH Database of Cognitive Training and Remediation Studies and a separate study. Approximately half the participants received CR and the rest were allocated to a control condition. All participants were assessed before and after therapy and at follow-up. Expressive negative symptoms and social amotivation symptoms scores were calculated from the Positive and Negative Syndrome Scale. WM was assessed with digit span and letter-number span tests.

Results. Participants who received CR had a significant improvement in WM scores ($d=0.27$) compared with those in the control condition. Improvements in social amotivation levels approached statistical significance ($d=−0.19$), but change in expressive negative symptoms did not differ between groups. WM change did not mediate the effect of CR on social amotivation.

Conclusions. The results suggest that a course of CR may benefit behavioural negative symptoms. Despite hypotheses linking memory problems with negative symptoms, the current findings do not support the role of this cognitive domain as a significant mediator. The results indicate that WM improves independently from negative symptoms reduction.

Received 2 November 2016; Revised 1 March 2017; Accepted 1 March 2017

Key words: Cognition, schizophrenia, negative symptoms, working memory, psychosis.

Introduction

Despite the significance of negative symptoms to the prognosis of schizophrenia treatment options for this symptom cluster are still relatively limited (Messinger et al. 2011; Fusar-Poli et al. 2015). This may be because we have not defined a target that may impact on these symptoms. One potential mediator has been identified in recent empirical and theoretical work which links negative symptoms and cognitive deficits in people with schizophrenia. In particular, Gold et al. (2008) suggest that problems in working memory (WM) may disrupt motivation and the pleasure experience. These authors hypothesised that, in order to recruit motivational resources, individuals use WM to represent events and forecast pleasure. According to this model, deficits in WM could limit the ability to accurately retrieve and use information to motivate and guide future behaviour. This theory has some empirical support as WM performance predicts the accuracy of past pleasure experience (Burbridge & Barch, 2007). More recently, activity in WM brain networks has been associated with improvement in negative symptoms following antipsychotic initiation suggesting that WM may interact with treatment to influence outcomes (Nejad et al. 2013). Although a number of hypotheses have been proposed the latter study is the only one to investigate the mediating effect of WM on negative symptoms changes in the context of an intervention.

Although not an elective target for cognitive remediation (CR), the most recent meta-analysis reported that CR has a small but significant effect on symptoms of...
schizophrenia (Wykes et al. 2011). Among studies reporting a positive effect, the majority suggest that the negative symptom cluster is more likely to improve after CR compared with the positive symptom cluster (e.g. Ghareaeipour & Scott, 2012; Farrerney et al. 2013; Sanchez et al. 2014; Cella et al. 2014b). The effect of CR on negative symptoms is consistent with associations between negative symptoms and cognitive problems often found in patients with schizophrenia (Milev et al. 2005; Ventura et al. 2009). Despite these encouraging results it is still relatively unclear which active ingredients of CR may contribute to negative symptom improvements. The framework proposed by Gold and co-workers (Gold et al. 2008; Gold et al. 2012) seems a potential candidate to explain how improvements in cognitive domains targeted by CR (e.g. WM) may influence negative symptoms. Indeed, based on this theory Strauss (Strauss, 2013) suggested that CR may be a useful intervention to tackle behavioural negative symptoms.

The current study investigates for the first time the potential benefit of CR for negative symptoms and tests the mediating role of WM as a possible cognitive mechanism. However, the domain of negative symptoms encompasses a wide range of problems, from social behaviour to motivation as well as difficulties in affect display and lack of spontaneity. In an attempt to reduce negative symptom heterogeneity, factor analytic studies have explored solutions that produce more coherent clusters. The overwhelming majority of these studies support two distinct domains: one characterised by expressive deficits, including flat affect and alogia, and the other characterised by behavioural problems such as avolition, asociality andanhedonia (Kirkpatrick and Fischer, 2006; Messinger et al. 2011). Distinguishing between these two sub-domains may be important in the context of intervention because the ‘active ingredients’ of therapies may have a selective effect on only one cluster. So in this study we consider these two distinct negative symptom dimensions characterised by: (i) lack of expressivity and (ii) poor social motivation. By exploring mediation pathways this study will test the framework proposed by Gold et al. (2008) in the context of an intervention. Change in WM produced by therapy will allow an evaluation of the links between negative symptoms and WM. By analysing the individual level data from different trials, this study will also allow an estimate of how consistent the results will be across different settings and allow a more accurate estimation of the effect size (Riley et al. 2010).

This study will not only explore the effects of CR on an understudied target but also investigate the mechanisms responsible for this change by examining potential mediational pathways. CR studies have preferentially focused on evaluating effectiveness, but paid only limited attention to study how effectiveness is achieved (i.e. therapy mechanisms). Work in this direction, even if exploratory, can prove important in improving current intervention approaches and maximise benefits.

In this study, we expect CR to have a selective effect on behavioural negative symptoms and anticipate, in line with Gold et al. (2008) that improvement in WM following CR will partly or fully mediate the change in behavioural but not expressive negative symptoms.

Method

This study used data included in the NIMH Database of Cognitive Training and Remediation Studies (DoCTRS). This database assembled data at the individual level from randomised, controlled trials of CR in people with schizophrenia. For this paper, we analysed data from three studies entered in DoCTRS (Wykes et al. 2007; Bell et al. 2008; Keefe et al. 2012) and data from an unpublished, non-DoCTRS study (Reeder et al. Submitted). This latter study is not yet included in the database as it was recently completed and currently under review for publication. These studies were selected because they all assessed WM and negative symptoms.

Design

In the four trials analysed, CR was compared with a control condition, randomisation was conducted independently and assessors were blind to group allocation. Treatment duration ranged from 12 to 16 weeks. Post-treatment follow-up periods ranged from 24 to 32 weeks. Participants were assessed at intake into the study (Baseline); at the end of treatment (Post-treatment) and at Follow-up. No therapy was provided between post-therapy and follow-up.

Participants

Participants had a primary diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV criteria and were aged 18–65 years. Exclusion criteria were neurological diseases, traumatic brain injury, a history of learning disability, current substance abuse and poor understanding of English. Participants were recruited in the UK (Wykes et al. 2007; Reeder et al. Submitted) and in the USA (Bell et al. 2007; Keefe et al. 2012).

Therapy

The CR employed consisted primarily of task practice engaging various cognitive domains, including WM,
attention, processing speed, long-term memory and executive function. Additional information on the different types of CR used and control conditions is summarised in Table 1.

Measures

Demographic and cognitive data

Basic demographic information was collected on all participants. Premorbid IQ was estimated using the WRAT-R (Kareken et al. 1995) or the NAART (Uttl, 2002). Scores were compared using the guidelines proposed by Johnstone et al. (1996).

Symptoms

Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS, Kay et al. 1987). This is a 30-item measure of symptom severity for people with schizophrenia. The measure is administered as a clinical interview by a trained researcher or clinician. Each item is scored on a 7-point scale ranging from not symptomatic (i.e. 1) to extremely severe symptom (i.e. 7). For this study, we scored the PANSS according to Liemburg et al. (2013) and used the two dimensions of negative symptoms identified in their study: Expressive Negative Symptoms (i.e. flat affect, poor rapport, lack of spontaneity, mannerisms and posturing, motor retardation and avolition) and social amotivation (emotional withdrawal, passive/apathetic social withdrawal and active social avoidance).

Working memory

WM was assessed using two well-established tests: the Digit Span test from the Wechsler Adult Intelligence Scale (WAIS–III; Wechsler, 1987) and the Letter-Number Span from the MATRICS Consensus Cognitive Battery (Nuechterlein et al. 2008). Only Keefe et al. (2012) used the Letter-Number Span. Scores on these tests are reported in standardised Z-scores.

Analysis

The analysis was conducted in two stages. First, we investigated whether individuals randomised to CR showed greater improvement in WM and symptoms compared with TAU at Post-treatment and Follow-up assessments. We conducted a mixed effects analysis based on the intention-to-treat principle. The baseline score of the outcome variable was included as a covariate [analysis of covariance (ANCOVA) approach]. The model considered time (i.e. both Baseline and Follow-up assessments), treatment group and the interaction between time and group as fixed

Table 1. Description of the CR interventions considered

| Intervention | Bell et al. (2008) | Keele et al. (2012) | Reeder et al. (submitted) |
|--------------|-------------------|--------------------|--------------------------|
| Neurocognitive enhancement therapy + Social information-processing group + Vocational rehabilitation | 28 | 8-12 | 12 |
| Post-science brain fitness auditory training + Bridging group | 24 sessions | 3 sessions | 25.5 sessions |
| CIRCuits is a web-based computerised therapy targeting metacognition | 113h | Vocational rehabilitation | Treatment as usual |
| Paper and pencil cognitive remediation tasks | | Computer games + Healthy lifestyle groups | Therapists supported participants throughout the intervention |
| Therapists supported participants for social information processing groups | | | |

Contact with therapist

Therapists supported participants for bridging groups |

Post-therapy assessment (weeks) | 52 | 12 |

Follow-up assessment (in months) | 104 |

* All active control conditions were matched for contact time.
categorical variables. Study was also included as a categorical fixed factor. An unstructured covariance matrix allowing unequal variances and covariances (i.e. correlations) between repeated measures and study was used to account for repeated observations over time (Brown & Prescott, 2006). Maximum-likelihood estimation was used to estimate parameters for models analysing all available data in the presence of missing data, including no observations in Keefe at follow-up (Brown & Prescott, 2006).

Interactions between study and time or treatment, respectively, were assessed using the Bayesian information criteria (BIC). Model selection was performed by assessing change in BIC values with changes larger than 10 providing evidence in support of excluding interaction terms (Raftery, 1995). BIC changes were only reported if the $p$ value for the interaction statistics was smaller than 0.1. Cohen’s $d$ (i.e. predicted mean difference divided by baseline standard deviation) is presented as an estimate of effect size.

Sensitivity analyses were conducted to control for individual studies unduly influencing the results. We reran the models: (i) without Keefe et al. to control for missing observations at follow-up, (ii) without each of the other studies in turn to control for potential difference in treatments and (iii) including only participants with completed cases to assess if people with missing data influence the results of the analysis. As WM and negative symptoms vary by age, we conducted a further sensitivity analyses, including age as a covariate in the model. We will report the results of these analyses only when they alter the primary analysis results.

In the second stage, we performed a path analysis to assess possible mediating effects (Baron & Kenny, 1986; MacKinnon & Luecken, 2008). Mediation is a hypothesised causal chain in which one independent variable (i.e. CR) affects a mediating variable (i.e. WM), which, in turn, affects the outcome variable (i.e. social amotivation or expressive negative symptoms).

Multiple-group path analysis was employed to examine and test whether differences in the path parameters across studies were statistically significant. Testing for cross-group invariance involved comparing a baseline model where all parameters were constrained to be invariant between the groups with a model where no constraints were specified. Path models were fitted using full maximum-likelihood estimation. The Sobel test was used to calculate standard errors of the indirect effects. Comparison of nested models employed a nested Chi-square ($\chi^2$) test. For all variables we included a path to control for baseline differences in the measures (ANCOVA approach; MacKinnon, 2008). Mixed effects model analyses used STATA 13.1 and path analyses using AMOS 22.

Results

Data from 309 participants who completed the baseline assessment and were randomised were included in the analyses (i.e. 157 CR and 152 control). Table 1 shows the demographic and clinical characteristics of the two groups at baseline. Positive and general symptoms did not change over time in either groups (Table 2).

Does CR directly affect WM?

Participants who received CRT significantly improved their WM compared to those in the control groups at Post-treatment [mean difference: 0.31 (95% CI 0.12–0.50), $z = 3.16, p = 0.002, d = 0.27$], but the difference was not significant at Follow-up [mean difference: 0.10 (95% CI −0.10 to 0.30), $z = 1.02, p = 0.31, d = 0.09$]. There was no main effect of study on WM [χ² (3) = 2.74, $p = 0.43$]. The interactions between time and study ($p = 0.83$) and treatment group and study ($p = 0.62$) were not significant and therefore not included in the model. Adding age as a covariate did not influence the outcome ($p = 0.26$).

Does CR directly affect social amotivation?

The mixed model analyses at post-treatment revealed a trend towards a significant interaction between treatment group and time for social amotivation after controlling for social amotivation baseline [mean difference 0.76 (−0.05 to 1.57) $z = 1.85, p = 0.07, d = 0.11$]. Participants who received CR showed a significant benefit compared with those in the control groups at post-treatment [mean difference: −1.29 (95% CI −1.79 to −0.78), $z = −4.99, p < 0.0001, d = −0.19$], but this difference was not maintained at follow-up [mean difference: −0.53 (95% CI −1.34 to 0.29), $z = −1.27, p = 0.21, −0.08$]. There were no significant differences between study sites ($p = 0.27$). The interactions between time and study ($p = 0.63$) and treatment group and study ($p = 0.53$) were not significant and not included in the final model. Adding age as a covariate did not influence this result ($p = 0.6$).

Does CR directly affect expressive negative symptoms?

There were no significant differences in expressive negative symptoms between CR and the control group at Post-treatment [mean difference between CR and TAU = −0.11 (95% CI −0.87 to 0.66), $z = −0.28, p = 0.78, d = 0.01$] or Follow-up [−0.11 (95% CI −0.97 to 1.05), $z = 0.08, p = 0.94, d = 0.01$]. There were significant differences between studies [$\chi^2(3) = 7.86, p = 0.049$]. The interaction between treatment group and time was not significant [0.15, (95% CI −0.91 to 1.21), $z = 0.28, p = 0.82, d = 0.01$]. The interactions between
Indirect effects of individual studies ranged from $b_{-0.63}$, $p_{st.b.} = 0.05$ and were all non-significant. Differences among source studies. Standardised indirect effects of individual studies ranged from $d_{-0.132}$ to 0.116, $z = 1.01$, $p = 0.31$, st. beta: $-0.001$. Indirect effects of individual studies ranged from $-0.155$ to 0.027 (standardised betas from $-0.017$ to 0.003, all non-significant).

### Discussion

Our results further point to a possible beneficial effect of CR on negative symptoms. These analyses, however, show that improvements may only apply to a sub-set of negative symptoms characterised by less expressive and more behavioural features. This effect is evident, at trend significance level, immediately following therapy, but not retained at follow-up. Increasingly, research reports suggest that negative symptom heterogeneity may be a significant factor to consider when evaluating the effects of treatment (Levine & Leucht, 2014). Recent research showed that this is the case in CR for people with schizophrenia (Cella et al. 2014) and supports the use of more homogeneous and empirically defined symptoms cluster when evaluating treatment effects. The results of previous studies exploring the effects of CR on the symptoms of schizophrenia might have suffered from conflating information from scales that use heterogeneous symptom clusters with mixed associations with cognitive problems.

Contrary to our hypothesis, the current results suggest that WM does not mediate the effect of CR on social amotivation. This result is at odds with the model proposed suggesting that WM deficits negatively influence reward-related processes and contribute to behavioural negative symptoms (Gold et al. 2008). We demonstrated that in the context of an intervention targeting cognitive difficulties, improvement

### Table 2. Demographics and clinical characteristics for the two groups

|               | CR (N = 157) | Control (N = 152) |
|---------------|--------------|------------------|
| Gender (male) | 68.2%        | 66.9%            |
| Age (years)   | 38.3(10.3)   | 37.1(9.7)        |
| Education (years) | 12.8(2.3) | 12.4(2.4)        |
| Illness onset over 10 years ago | 56.1% | 53.7% |
| Premorbid IQ | 93.5(13.1) | 91.7(13.6) |
| PANSS Positive | 13.4(5.7) | 14(5.9) |
| PANSS Negative | 15.1(6.6) | 15.9(6.9) |
| PANSS General | 30.8(9.2) | 31.2(9.5) |
| Demographics and clinical characteristics for the two groups |

The PANSS factors scores presented are according to Kay et al. (1987).

### Table 3. Means and standard deviations for expressive negative symptoms, (Exp Neg), social amotivation (Soc Amot) and working memory (WM) for control group and the cognitive remediation (CR) groups at the three assessments points

|                  | Control Mean (s.d.) | N | CR Mean (s.d.) | N |
|------------------|---------------------|---|----------------|---|
| Exp Neg Baseline | 11.47 (5.25)        | 149 | 11.70 (5.10)  | 156 |
| Exp Neg Post-treatment | 10.88 (4.66) | 137 | 10.95 (4.54) | 146 |
| Exp Neg Follow-up  | 10.51 (4.83)        | 93  | 10.87 (4.17) | 93  |
| Soc Amot Baseline | 6.86 (2.84)         | 149 | 7.2 (2.89)    | 156 |
| Soc Amot Post-treatment | 7.19 (3.1)  | 139 | 6.11 (2.56) | 148 |
| Soc Amot Follow-up | 6.5 (3.4)          | 101 | 6.18 (2.93)  | 97  |
| WM Baseline      | $-0.79 (1.21)$      | 147 | $-0.73 (1.11)$ | 154 |
| WM Post-treatment | $-0.74 (1.24)$     | 136 | $-0.39 (1.03)$ | 142 |
| WM Follow-up     | $-0.67 (1.25)$      | 99  | $-0.55 (1.01)$ | 101 |

Example:

- $t_{-0.63}$, $p_{st.b.} = 0.05$
- $d_{-0.132}$ to 0.116, $z = 1.01$, $p = 0.31$, st. beta: $-0.001$.

- Indirect effects of individual studies ranged from $-0.155$ to 0.027 (standardised betas from $-0.017$ to 0.003, all non-significant).

- Indirect effects of individual studies ranged from $-0.63$, $p_{st.b.} = 0.05$ and were all non-significant. Differences among source studies. Standardised indirect effects of individual studies ranged from $-0.132$ to 0.116, $z = 1.01$, $p = 0.31$, st. beta: $-0.001$.

- Indirect effects of individual studies ranged from $-0.155$ to 0.027 (standardised betas from $-0.017$ to 0.003, all non-significant).

### Discussion

Our results further point to a possible beneficial effect of CR on negative symptoms. These analyses, however, show that improvements may only apply to a sub-set of negative symptoms characterised by less expressive and more behavioural features. This effect is evident, at trend significance level, immediately following therapy, but not retained at follow-up. Increasingly, research reports suggest that negative symptom heterogeneity may be a significant factor to consider when evaluating the effects of treatment (Levine & Leucht, 2014). Recent research showed that this is the case in CR for people with schizophrenia (Cella et al. 2014) and supports the use of more homogeneous and empirically defined symptoms cluster when evaluating treatment effects. The results of previous studies exploring the effects of CR on the symptoms of schizophrenia might have suffered from conflating information from scales that use heterogeneous symptom clusters with mixed associations with cognitive problems.

Contrary to our hypothesis, the current results suggest that WM does not mediate the effect of CR on social amotivation. This result is at odds with the model proposed suggesting that WM deficits negatively influence reward-related processes and contribute to behavioural negative symptoms (Gold et al. 2008). We demonstrated that in the context of an intervention targeting cognitive difficulties, improvement
in WM did not contribute to negative symptom change and improvements in these domains occurred independently. This does not rule out the contribution of WM or cognition to negative symptoms. In this study, we could only assess the role of verbal WM on negative symptoms because of the assessment measures used. It is possible, as some studies suggested that visual WM may be contributing more strongly to negative symptoms severity (Pantelis et al. 2001). Alternatively, other cognitive domains may be contributing to negative symptoms. Difficulties in planning and organising information may contribute to disorganised behaviour, decreased motivation and less pleasure from experience. Indeed, some research suggests that this may be the case but no specific theory of the mechanism has yet been advanced (Fraguas et al. 2014). The set of studies considered in the DoCTRS, database did not allow an investigation of the contribution of executive function because executive function was measured using different tests assessing different competencies that only marginally overlapped (e.g. planning, shifting, inhibition). A planned expansion of the DoCTRS database would allow exploration of this question in the future.

Studies exploring the effects of CR on basic cognitive processes may help us refine our understanding of potential translational mechanism and their relevance to specific symptoms such as the negative symptoms (Cella et al. 2015). An example of a promising translational mechanism for negative symptoms is reward sensitivity. Poor sensitivity to feedback has been extensively documented in people with psychosis and is associated with both cognitive difficulties and negative symptom severity (e.g. Gold et al. 2008; Strauss et al. 2014). A recent study showed that a course of CR is associated with improved sensitivity to feedback and that improvements in this domain are linked to negative symptoms reduction (Cella et al. 2014a). Future studies should specifically explore the role of reward sensitivity in the context of interventions tackling negative symptoms as this may be a promising mediator.

Alongside improving cognition it is possible that CR may exert a positive effect on negative symptoms via ‘non-specific’ therapy elements including therapeutic alliance and behavioural activation (e.g. session attendance) (e.g. Huddy et al. 2012). These aspects are only beginning to be explored and may be particularly important for negative symptoms as they provide social contact opportunities and promote goal-directed behaviour.

There are a limited number of interventions currently available for negative symptoms and these were found to have only a small effect (Fusar-Poli et al. 2015). A recent meta-analysis suggested that CR interventions have a moderate effect size on negative symptoms and that this effect is largely durable (Cella et al. 2016). The results of this study also suggest that CR programmes using rehabilitation activities alongside cognitive task practice and frequent personal contact with a facilitator or therapist tend to have a higher impact on negative symptoms. It is likely that...
by providing these elements these programs facilitated learning consolidation and the use of new skills in everyday life. This study demonstrates a similar effect, but in the context of interventions that did not always provide additional rehabilitation activities and intensive therapist contacts. It is possible that by enhancing these two components and focusing task practice on the cognitive domains more strongly associated with negative symptoms a much larger symptom reduction could be observed.

A number of small studies have already attempted to adapt established psychological interventions for psychosis to include a more pronounced focus on negative symptoms; however, the results are not very encouraging (Velthorst et al. 2015). The current study used a different approach and took advantage of a database of completed studies to investigate the presence of a ‘signal’. This approach has the benefit of reducing possible bias associated with a therapy delivery method by combining the results of different studies. This approach is efficient as it can be used to test hypotheses without the need to collect new data. Recent evidence suggests that using aggregates of individual data should be preferred, where possible, to traditional meta-analytic studies (Riley et al. 2010). Some of the advantages of this methodology include: screening for missing data, including recruitment site in the analysis, replicating results, using standardised analysis across different studies, testing model assumption (e.g. complex interactions between time, treatments and sites) and consistently adjusting for baseline variables. Studies comparing the results of individual data meta-analysis to traditional meta-analytic approaches have shown that differences in the results between these two methods can be sizable and influence practice (e.g. Berlin et al. 2002; McCormack et al. 2004). This method is preferred as the best source of evidence and should be used more often in mental health research to consolidate current evidence and inform best practice.

This study has limitations. The PANSS, despite assessing negative symptoms, was not designed to capture specific components of this symptom clusters and it may be that the factors used for this study only account for some features of these domains. Although our analysis did not highlight any study behaving as an outlier, it is possible that there may be a group of studies that behave differently and that this trend is not evident due to the restricted numbers of studies. There is a considerable variability in the neuropsychological assessment measures used by different studies and this limits the possibility of aggregating data.

The current analyses also suggest that treatment-related gains in WM and social amotivation may not be maintained at follow-up. This result is at odds with the most recent meta-analysis, which suggests that cognitive gains are durable (Wykes et al. 2011). The studies included in our analysis, with the exception of Bell et al. (2008), did not provide CR in the context of other comprehensive rehabilitation interventions. There is increasing support for the notion that CR achieves more durable gains when delivered alongside rehabilitation (McGurk et al. 2007; Bowie et al. 2012). With the majority of the programmes considered here not offering additional support, it is possible that the lack of treatment gain retention may be dependent on lack of opportunities to apply CR gains in a wider rehabilitative context.

Acknowledgements

No financial support was received for this work. All authors have no financial interests related to the results presented in this manuscript. The authors wish to thank Dr Heinssen, from NIH, for his instrumental role in the creation of the DoCTRS database and for his comments on the current manuscript. The National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London supports MC, DS and TW.

Declaration of Interests

All authors have no conflict of interest.

References

Baron RM, Kenny DA (1986). The moderator mediator variable distinction in social psychological research – conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology 51, 1173–1182.

Bell M, Fiszdon J, Greig T, Wexler B, Bryson G (2007). Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. Journal of Rehabilitation Research and Development 44, 761–770.

Bell MD, Zito W, Greig T, Wexler BE (2008). Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up. Schizophrenia Research 105, 18–29.

Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI, ANTI-LYMPHOCYTE ANTIBODY INDUCTION THERAPY STUDY G (2002). Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Statistics in Medicine 21, 371–387.

Bowie CR, Mcgurk SR, Mausbach B, Patterson TL, Harvey PD (2012). Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition,
functional competence, and real-world behavior. American Journal of Psychiatry 169, 710–718.
Brown H, Prescott R (2006). Applied Mixed Models in Medicine. Hoboken, NJ: John Wiley: Chichester, England.
Burbridge JA, Barch DM (2007). Anhedonia and the experience of emotion in individuals with schizophrenia. Journal of Abnormal Psychology 116, 30–42.
Cella M, Bishara AJ, Medin E, Swan S, Reeder C, Wykes T (2014a). Identifying cognitive remediation change through computational modeling – effects on reinforcement learning in schizophrenia. Schizophrenia Bulletin 40, 1422–1432.
Cella M, Preti A, Edwards C, Dow T, Wykes T (2016). Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clinical Psychology Review 52, 43–51.
Cella M, Reeder C, Wykes T (2014b). It is all in the factors: effects of cognitive remediation on symptom dimensions. Schizophrenia Research 156, 60–62.
Cella M, Reeder C, Wykes T (2015). Cognitive remediation in schizophrenia — now it is really getting personal. Current Opinion in Behavioural Sciences 4, 147–151.
Farenny A, Aguado J, Ochoa S, Harn J, Usall J (2013). The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophrenia Research 190, 38–63.
Fraguas D, Merchán-Naranjo J, Del Rey-Mejías A, Castro-Fornieles J, Gonzalez-Pinto A, Rapado-Castro M, Pina-Camacho L, Díaz-Caneja CM, Graell M, Otero S, Baeza I, Moreno C, Martínez-Cengotitabengoa M, Rodríguez-Toscano E, Arango C, Parelладa M (2014). A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. Schizophrenia Research 158, 126–133.
Fusar-Poli P, Papana-stasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (2015). Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophrenia Bulletin 41, 892–899.
Gharaeipour M, Scott BJ (2012). Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients. Schizophrenia Research 142, 165–170.
Gold JM, Barch DM, Carter CS, Dakin S, Luck SJ, Macdonald III AW, Ragland JD, Ranganath C, Kovacs I, Silverstein SM, Strauss M (2012). Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. Schizophrenia Bulletin 38, 144–152.
Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA (2008). Reward processing in schizophrenia: a deficit in the representation of value. Schizophrenia Bulletin 34, 835–847.
Huddy V, Reeder C, Kontis D, Wykes T, Stahl D (2012). The effect of working alliance on adherence and outcome in cognitive remediation therapy. Journal of Nervous and Mental Disease 200, 614–619.
Johnstone B, Callahan CD, Kapila C, Bouman DE (1996). The comparability of the WRAT-R reading test and NAART as estimates of premorbid intelligence in neurologically impaired patients. Archives of Clinical Neuropsychology 11, 513–519.
Kareken DA, Gur RC, Saykin AJ (1995). Reading on the wide range achievement test-revised and parental education as predictors of IQ: comparison with the Barona formula. Archives of Clinical Neuropsychology 10, 147–157.
Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
Keefe RS, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D’SOUZA DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, Haim AJ, Stroup TS (2012). Feasibility and pilot efficacy results from the multisite cognitive remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. Journal of Clinical Psychiatry 73, 1016–1022.
Kirkpatrick B, Fischer B (2006). Subdomains within the negative symptoms of schizophrenia: commentary. Schizophrenia Bulletin 32, 246–249.
Levine SZ, Leucht S (2014). Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophrenia Research 156, 107–114.
Liemburg E, Castelein S, Stewart R, Van Der Gaag M, Aleman A, Knektnering H (2013). Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. Journal of Psychiatry Research 47, 718–725.
Mackinnon DP (2008). Introduction to Statistical Mediation Analysis. Lawrence Erlbaum Associates: New York.
Mackinnon DP, Luecken LJ (2008). How and for whom? Mediation and moderation in health psychology. Health Psychology 27, 599–510.
McCormack K, Grant A, Scott N, COLLABORATION EUHT (2004). Value of updating a systematic review in surgery using individual patient data. British Journal of Surgery 91, 495–499.
Megurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A (2007). Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. American Journal of Psychiatry 164, 437–441.
Messinger JW, Tremewan F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D (2011). Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clinical Psychology Review 31, 161–168.
Milev P, Ho BC, Arndt S, Andreasen NC (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry 162, 495–506.
Najad AB, Madsen KH, Ebdrup BH, Siebner HR, Rasmussen H, Aggneraes B, Glenthøj BY, Baare WF (2013). Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients. International Journal of Neuropsychopharmacology 16, 1195–1204.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese III FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H,
Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008). The MATRICS Consensus Cognitive Battery. Part 1: test selection, reliability, and validity. American Journal of Psychiatry 165, 203–213.

Pantelis C, Stuart GW, Nelson HE, Robbins TW, Barnes TR (2001). Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. American Journal of Psychiatry 158, 1276–1285.

Raftery AE (1995). Bayesian model selection in social research. Sociological Methodology 25, 111–163.

Reeder C, Landau S, Huddy V, Greenwood K, Cella M, Wykes T (Submitted). A new computerised metacognitive Cognitive Remediation programme for schizophrenia (CIRCuiTS): a randomised controlled trial.

Riley RD, Lambert PC, Abo-Zaid G (2010). Meta-analysis of individual participant data: rationale, conduct, and reporting. British Medical Journal 340, c221.

Sanchez P, Pena J, Bengoetxea E, Ojeda N, Elizagarate E, Ezcurra J, Gutierrez M (2014). Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial. Schizophrenia Bulletin 40, 707–715.

Strauss GP (2013). Translating basic emotion research into novel psychosocial interventions for anhedonia. Schizophrenia Bulletin 39, 737–739.

Strauss GP, Waltz JA, Gold JM (2014). A review of reward processing and motivational impairment in schizophrenia. Schizophrenia Bulletin 40(Suppl 2), S107–S116.

Uttl B (2002). North American Adult Reading Test: age norms, reliability, and validity. Journal of Clinical and Experimental Neuropsychology 24, 1123–1137.

Velthorst E, Koeter M, Van Der Gaag M, Nieman DH, Fett AK, Smit F, Staring AB, Meijer C, De Haan L (2015). Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychological Medicine 45, 453–465.

Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH (2009). Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophrenia Research 113, 189–199.

Wechsler D (1987). Manual for the Wechsler Memory Scale-Revised. The Psychological Corporation: San Antonio, TX.

Wykes T, Huddy V, Cellard C, Mcgurk SR, Czobor P (2011). A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. American Journal of Psychiatry 168, 472–483.

Wykes T, Reeder C, Landau S, Everitt B, Knapp M, Patel A, Romeo R (2007). Cognitive remediation therapy in schizophrenia: randomised controlled trial. British Journal of Psychiatry 190, 421–427.